MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
Filed second provisional new composition of matter patent application for MAIA’s third entirely home-grown telomere-targeting molecule Reported 35 patients enrolled as of July 2023 in THIO-101...
Source: marketscreener.com